| 引用本文: | 蔡宏文,徐慧敏,何亚男,戴海斌,俞凌燕,颜小锋.硫糖铝与抑酸剂联用与单用比较的Meta分析[J].中国现代应用药学,2012,29(9):852-857. |
| CAI Hongwen,XU Huimin,HE Ya’nan,DAI Haibin,YU Lingyan,YAN Xiaofeng.Meta-analysis: Effect of Monotherapy and Combination Therapy with Sucralfate and Acid Secretion Inhibitor[J].Chin J Mod Appl Pharm(中国现代应用药学),2012,29(9):852-857. |
|
| 摘要: |
| 目的 系统评价硫糖铝与抑酸剂联用的有效性和安全性。方法 计算机检索Cochrane图书馆临床对照试验资料库(2011年第4期)、MEDLINE、EMbase、中国生物医学文献数据库和中国期刊全文数据库(从建库至2011年11月)。由两位研究者按纳入与排除标准选择随机对照研究评价质量及提取资料后，采用RevMan 4.2软件对数据进行Meta分析。结果 初检出11篇文献，经筛选最终纳入7篇文献共7个随机对照研究，包括595例患者。Meta分析结果显示，硫糖铝与抑酸剂联用与单药相比，临床症状有效率[OR 1.6，95%CI(0.87，2.93)，P=0.13]、胃镜治愈率[OR 1.36，95%CI(0.87，2.12)，P=0.17]、不良反应发生率[OR 1.36，95%CI(0.64，2.90)，P=0.42]，均无统计学差异。结论 现有研究结果表明，硫糖铝与抑酸剂联用与单药相比，未能显著增加疗效和减少不良反应，不优于两者单用。 |
| 关键词: 硫糖铝 抑酸剂 H2受体阻滞剂 质子泵抑制剂 Meta分析 |
| DOI： |
| 分类号: |
| 基金项目:浙江省教育厅科研项目(Y200908690)；浙江省中医药科学研究基金(2010ZA070) |
|
| Meta-analysis: Effect of Monotherapy and Combination Therapy with Sucralfate and Acid Secretion Inhibitor |
|
CAI Hongwen1, XU Huimin2, HE Ya’nan2, DAI Haibin2, YU Lingyan2, YAN Xiaofeng2
|
|
1.The First Affiliated Hospital, Zhejiang Chinese Medical University, Hangzhou 310006, China;2.The Second Affiliated Hospital，School of Medicine, Zhejiang University, Hangzhou 310009, China
|
| Abstract: |
| OBJECTIVE To evaluate the efficacy and safety of combined sucralfate and acid secretion inhibitor. METHODS The Cochrane Central Register of Controlled Trials (Issue 4, 2011), MEDLINE, EMbase, CBM and CNKI (from their inception to November 2011) were searched for relevant studies. Two reviewers independently retrieved randomized controlled trials (RCTs) according to the inclusion and exclusion criteria, assessed the methodological quality of included trials, and extracted data. Meta-analysis was performed by RevMan 4.2 soft. RESULTS Seven RCTs involving 595 patients were ultimately identified. The results of meta-analyses showed combination therapy was not superior to monotherapy in symptom improvement [OR 1.6, 95%CI (0.87, 2.93), P=0.13], endoscopic healing [OR 1.36, 95%CI (0.87, 2.12), P=0.17] and adverse events [OR 1.36, 95%CI (0.64, 2.90), P=0.42]. CONCLUSION Combination therapy with sucralfate and acid secretion inhibitor provides no superior in efficacy and safety than monotherapy． |
| Key words: sucralfate acid secretion inhibitor H2-receptor antagonist proton pump inhibitor meta-analysis |
